These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28449702)

  • 1. Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial.
    Verma V; Bhirud AR; Denniston KA; Bennion NR; Lin C
    Radiat Oncol; 2017 Apr; 12(1):71. PubMed ID: 28449702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial.
    Verma V; Lazenby AJ; Zheng D; Bhirud AR; Ly QP; Are C; Sasson AR; Lin C
    Radiother Oncol; 2017 Mar; 122(3):464-469. PubMed ID: 28089484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
    Lin C; Verma V; Ly QP; Lazenby A; Sasson A; Schwarz JK; Meza JL; Are C; Li S; Wang S; Hahn SM; Grem JL
    Radiother Oncol; 2019 Mar; 132():55-62. PubMed ID: 30825970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
    Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
    Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
    Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA
    Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
    Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
    Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
    Wild AT; Herman JM; Dholakia AS; Moningi S; Lu Y; Rosati LM; Hacker-Prietz A; Assadi RK; Saeed AM; Pawlik TM; Jaffee EM; Laheru DA; Tran PT; Weiss MJ; Wolfgang CL; Ford E; Grossman SA; Ye X; Ellsworth SG
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):571-9. PubMed ID: 26867885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.
    Schellenberg D; Kim J; Christman-Skieller C; Chun CL; Columbo LA; Ford JM; Fisher GA; Kunz PL; Van Dam J; Quon A; Desser TS; Norton J; Hsu A; Maxim PG; Xing L; Goodman KA; Chang DT; Koong AC
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):181-8. PubMed ID: 21549517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
    Schellenberg D; Goodman KA; Lee F; Chang S; Kuo T; Ford JM; Fisher GA; Quon A; Desser TS; Norton J; Greco R; Yang GP; Koong AC
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):678-86. PubMed ID: 18395362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
    Park JJ; Hajj C; Reyngold M; Shi W; Zhang Z; Cuaron JJ; Crane CH; O'Reilly EM; Lowery MA; Yu KH; Goodman KA; Wu AJ
    Acta Oncol; 2017 Dec; 56(12):1746-1753. PubMed ID: 28661823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.
    Lin C; Verma V; Lazenby A; Ly QP; Berim LD; Schwarz JK; Madiyalakan M; Nicodemus CF; Hollingsworth MA; Meza JL; Are C; Padussis J; Grem JL
    Am J Clin Oncol; 2019 Oct; 42(10):755-760. PubMed ID: 31513018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.
    Mahadevan A; Jain S; Goldstein M; Miksad R; Pleskow D; Sawhney M; Brennan D; Callery M; Vollmer C
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):735-42. PubMed ID: 20171803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial.
    Taniguchi CM; Frakes JM; Aguilera TA; Palta M; Czito B; Bhutani MS; Colbert LE; Abi Jaoude J; Bernard V; Pant S; Tzeng CD; Kim DW; Malafa M; Costello J; Mathew G; Rebueno N; Koay EJ; Das P; Ludmir EB; Katz MHG; Wolff RA; Beddar S; Sawakuchi GO; Moningi S; Slack Tidwell RS; Yuan Y; Thall PF; Beardsley RA; Holmlund J; Herman JM; Hoffe SE
    Lancet Oncol; 2023 Dec; 24(12):1387-1398. PubMed ID: 38039992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
    Dholakia AS; Chaudhry M; Leal JP; Chang DT; Raman SP; Hacker-Prietz A; Su Z; Pai J; Oteiza KE; Griffith ME; Wahl RL; Tryggestad E; Pawlik T; Laheru DA; Wolfgang CL; Koong AC; Herman JM
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):539-46. PubMed ID: 24751410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
    Shen ZT; Zhou H; Li AM; Ji XQ; Jiang CC; Yuan X; Li B; Zhu XX; Huang GC
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):417-428. PubMed ID: 31667573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma.
    Yamamoto T; Kadoya N; Takeda K; Matsushita H; Umezawa R; Sato K; Kubozono M; Ito K; Ishikawa Y; Kozumi M; Takahashi N; Katagiri Y; Onishi H; Jingu K
    Radiat Oncol; 2016 May; 11():72. PubMed ID: 27229710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.
    Tozzi A; Comito T; Alongi F; Navarria P; Iftode C; Mancosu P; Reggiori G; Clerici E; Rimassa L; Zerbi A; Fogliata A; Cozzi L; Tomatis S; Scorsetti M
    Radiat Oncol; 2013 Jun; 8():148. PubMed ID: 23799996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration.
    Polistina F; Costantin G; Casamassima F; Francescon P; Guglielmi R; Panizzoni G; Febbraro A; Ambrosino G
    Ann Surg Oncol; 2010 Aug; 17(8):2092-101. PubMed ID: 20224860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric predictors of hematologic toxicity in patients undergoing concurrent gemcitabine-based chemoradiation for localized pancreatic cancer.
    Shaikh T; Wang LS; Egleston B; Burki M; Hoffman JP; Cohen SJ; Meyer JE
    Pract Radiat Oncol; 2016; 6(4):e107-e115. PubMed ID: 27032572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.